Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
Go back to Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival| ImaRx Therapeutics, Inc. (NASDAQ: IMRX) | Delayed: 4.61 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.61 | 52 Week High | $0.04 | |||
| Open | $4.61 | 52 Week Low | $0.00 | |||
| Day High | $4.61 | P/E | N/A | |||
| Day Low | $4.61 | EPS | $-0.09 | |||
| Volume | 26,702 | |||||
